Hot Medical Stocks To Own For 2018

As a generation, millennials are often maligned for being bad with money and reluctant to grow up but they still probably need a will.

Of course anyone who owns an asset like a home, or who has a spouse or dependents should have a will a document that lists the deceaseds beneficiaries and last wishes but so should just about any other adult, even single millennials, experts said. Along with a will, they should have beneficiary designations for any employer-sponsored retirement accounts and a power of attorney, especially for medical decisions. You cant make a decision if youre medically incapable or if youre dead, said Leslie Beck, a financial adviser at Compass Wealth Management in Rutherford, N.J. While they tend to be less common among millennials, those two situations, its not like it never happens.

Hot Medical Stocks To Own For 2018: Banner Corporation(BANR)

Advisors’ Opinion:

  • [By Ben Levisohn]

    The twenty stocks in Worth’s basket are: Ameriprise Financial (AMP) Bank of America, Banner (BANR), Citigroup, Citizens Financial Group (CFG), East West Bancorp (EWBC), First NBC Bank Holding (FNBC), HFF (HF), KeyCorp(KEY), Legacy Texas Financial Group (LTXB), Lincoln National (LNC), Morgan Stanley, Old National Bancorp (ONB), PacWest Bancorp (PACW), PNC Financial Services Group (PNC), Principal Financial Group (PFG), Stifel Financial (SF), SVB Financial Group (SIVB), TCF Financial (TCB), and Wells Fargo.

Hot Medical Stocks To Own For 2018: Pain Therapeutics(PTIE)

Advisors’ Opinion:

  • [By Monica Gerson]

    The list of below stocks is notable as the shares have traded on sequentially increasing volume spanning the trading days from September 16 to September 20:

Hot Medical Stocks To Own For 2018: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Paul Ausick]

    ArQule Inc. (NASDAQ: ARQL) dropped about 23% Friday, to post a new 52-week low of $1.13 after closing at $1.47 on Thursday. The stock’s 52-week high is $2.17. Volume was about 15 times the daily average of around 150,000 shares. The biopharmaceutical company said this morning that a phase 3 trial of a cancer drug did not meet the primary endpoint of improving overall survival.

Hot Medical Stocks To Own For 2018: New York & Company Inc.(NWY)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of New York & Company, Inc. (NYSE: NWY) got a boost, shooting up 13 percent to $2.31 as the company posted upbeat quarterly results.

    The GEO Group Inc (NYSE: GEO) shares were also up, gaining 19 percent to $23.27. Following Thursday’s Department of Justice news regarding privately-managed prisons, GEO Group dropped on Thursday, but rebounded Friday after issuing a response to the DoJ.

  • [By Monica Gerson]

    New York & Company, Inc. (NYSE: NWY) shares dropped 42 percent to $1.72 after the company reported downbeat Q1 results and issued a weak Q2 forecast.

Hot Medical Stocks To Own For 2018: Coca-Cola Company (The)(KO)

Advisors’ Opinion:

  • [By Demitrios Kalogeropoulos]

    That’s why many investors shop among the short list ofDividend Aristocrats, which are companies that boast an unbroken streak of at least 25 years of consecutive payout raises. A few members of that elite group have fallen out of favor recently and could represent solid long-term buys. Below, we’ll look at the prospects for market-beating returns fromCoca-Cola(NYSE:KO),Target(NYSE:TGT), andLowe’s(NYSE:LOW).


    Beverage companies such as PepsiCo and The Coca-Cola Co. (KO)  have been struggling recently to boost sales of sugary, carbonated drinks as more and more consumers shift to healthier eating habits. PepsiCo has the upper hand, though, as it does not rely solely on beverages.

  • [By Shanthi Rexaline]

    See also: 3 Reasons Alcoa Is No Longer The Curtain-Raising Event Of Earnings Season

    5. DuPont
    Company: E I Du Pont De Nemours And Co (NYSE: DD). Date of Reporting: Tuesday, before the market open. EPS Estimate vs. Year-ago EPS: $1.29 versus $1.24. Revenue Estimate: $7.29 billion versus $7.06 billion. Stock Gain/Loss (year to date): 14.97 percent.
    6. AT&T
    Company: AT&T Inc (NYSE: T). Date of Reporting: Tuesday, after the market close. EPS Estimate vs. Year-ago EPS: $0.74 versus $0.72. Revenue Estimate: $39.82 billion versus $40.52 billion. Stock Gain/Loss (year to date): (-14.6 percent).
    7. Coca-Cola
    Company: The Coca-Cola Co (NYSE: KO). Date of Reporting: Wednesday, before the market open. EPS Estimate vs. Year-ago EPS: $0.58 versus $0.60. Revenue Estimate: $9.65 billion versus $11.52 billion. Stock Gain/Loss (year to date): 8.32 percent.
    8. Boeing
    Company: Boeing Co (NYSE: BA). Date of Reporting: Wednesday, before the market open. EPS Estimate vs. Year-ago EPS: $2.31 versus $2.47. Revenue Estimate: $23.07 billion versus $24.75 billion. Stock Gain/Loss (year to date): 36.03 percent.
    9. Procter & Gamble
    Company: Procter & Gamble Co (NYSE: PG). Date of Reporting: Thursday, before the market open. EPS Estimate vs. Year-ago EPS: $0.78 versus $0.79. Revenue Estimate: $16.02 billion versus $16.1 billion. Stock Gain/Loss (year to date): 4.98 percent.
    10. Verizon

  • [By Paul Ausick]

    The Coca-Cola Co. (NYSE: KO) traded up 1.02% at $45.88. The stock’s 52-week range is $39.88 to $46.98. Volume was about 30% below the daily average of around 9.6 million. The soft drink maker had no specific news.

  • [By Ben Levisohn]

    Yes, Coca-Cola (KO) announced a CEO swap last week, but that has nothing to do with Morgan Stanley’s decision to cut Coca-Cola to Equal Weight from Overweight. Morgan Stanley analyst Dara Mohsenian and team explain what did:

    Getty Images

    We view Coke valuation as fair here, given topline challenges, with results limited by secular health/wellness challenges in developed markets and by weak macros in emerging markets. We also are even more cautious on large cap multinationals in general, given direct and indirect impacts from a Trump administration: 1) less favorable relative tax benefits from policy changes than domestic centric manufacturers, 2) the indirect impact of a strengthening US dollar, and 3) lower leverage to a potential US macro recovery from greater fiscal spending (which will have less impact on defensive large cap staples). Our downgrade is not related to the recent CEO change. We view James Quincey favorably, and we expect (and encourage) him to push harder on the favorable strategic changes Coke announced in October 2014.

    No matter. Shares of Coca-Cola have advanced 0.2% to $41.62 at 12:36 p.m. today.

Hot Medical Stocks To Own For 2018: Diageo plc(DEO)

Advisors’ Opinion:

  • [By Jayson Derrick]

    Given this less than favorable outlook, the analysts downgrade Diageo plc (ADR) (NYSE: DEO)’s stock rating from Buy to Hold with a price target on the U.K.-listed stock of GBP25.50.

  • [By Leo Sun]

    Retirees should generally invest in companies with wide moats and solid dividends. In a previous article, I noted that AT&T and Unilever were easy-to-understand companies that were ideal for most retirement portfolios. Today, I’ll add two more companies to that list — alcoholic beverage giants Diageo (NYSE:DEO) and Anheuser-Busch InBev (NYSE:BUD).

  • [By Mark Fritz]


    Brown-Forman Corporation (NYSE: BF.B): Hold.
    Price Target: $46.00.

    Davide Campari Milano SpA (ADR) (OTC: DVDCY): Buy.
    Price Target: 7.40 euros.

    Diageo plc (ADR) (NYSE: DEO): Hold.
    Price Target: 25.50 pounds.

    Price Target: 98 euros.

    Price Target: 99 euros.

    The authors relied on U.S. Census data, industry sources and the National Survey on Drug Use and Health.

Leave a Reply

Your email address will not be published.